The total return over the past 12 months is -60.38% vs. +16.94% for the S&P 500. So far it's up -28.13% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (60.38%) | (3.35%) | (28.32%) | (31.74%) | N/A | N/A |
| Total Return CAGR | (60.38%) | (3.35%) | (28.32%) | (31.74%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
| Year | Start price | End price | CRBP Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $8.14 | $5.85 | (28.13%) | +14.51% | (42.64%) |
| 2025 | $11.80 | $8.14 | (31.02%) | +17.72% | (48.74%) |
| 2024 | $6.04 | $11.80 | +95.36% | +24.89% | +70.47% |
| 2023 | $3.33 | $6.04 | +81.38% | +26.19% | +55.19% |
| 2022 | $18.48 | $3.33 | (81.98%) | (18.17%) | (63.81%) |
| 2021 | $37.50 | $18.48 | (50.72%) | +28.74% | (79.46%) |
| 2020 | $163.80 | $37.50 | (77.11%) | +18.37% | (95.48%) |
| 2019 | $175.20 | $163.80 | (6.51%) | +31.22% | (37.73%) |
| 2018 | $213.00 | $175.20 | (17.75%) | (4.56%) | (13.19%) |
| 2017 | $253.50 | $213.00 | (15.98%) | +21.70% | (37.68%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
